Puma’s controversial cancer drug secures FDA approval
After much speculation, FDA has given the green light to Puma's investigational breast cancer therapy neratinib (Nerlynx). Pivotal data had shown marginal benefits and a high rate of side effects, blurring the line between risk and reward.